101
|
Lohmann P, Lerche C, Bauer EK, Steger J, Stoffels G, Blau T, Dunkl V, Kocher M, Viswanathan S, Filss CP, Stegmayr C, Ruge MI, Neumaier B, Shah NJ, Fink GR, Langen KJ, Galldiks N. Predicting IDH genotype in gliomas using FET PET radiomics. Sci Rep 2018; 8:13328. [PMID: 30190592 PMCID: PMC6127131 DOI: 10.1038/s41598-018-31806-7] [Citation(s) in RCA: 74] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2018] [Accepted: 08/28/2018] [Indexed: 01/22/2023] Open
Abstract
Mutations in the isocitrate dehydrogenase (IDH mut) gene have gained paramount importance for the prognosis of glioma patients. To date, reliable techniques for a preoperative evaluation of IDH genotype remain scarce. Therefore, we investigated the potential of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET radiomics using textural features combined with static and dynamic parameters of FET uptake for noninvasive prediction of IDH genotype. Prior to surgery, 84 patients with newly diagnosed and untreated gliomas underwent FET PET using a standard scanner (15 of 56 patients with IDH mut) or a dedicated high-resolution hybrid PET/MR scanner (11 of 28 patients with IDH mut). Static, dynamic and textural parameters of FET uptake in the tumor area were evaluated. Diagnostic accuracy of the parameters was evaluated using the neuropathological result as reference. Additionally, FET PET and textural parameters were combined to further increase the diagnostic accuracy. The resulting models were validated using cross-validation. Independent of scanner type, the combination of standard PET parameters with textural features increased significantly diagnostic accuracy. The highest diagnostic accuracy of 93% for prediction of IDH genotype was achieved with the hybrid PET/MR scanner. Our findings suggest that the combination of conventional FET PET parameters with textural features provides important diagnostic information for the non-invasive prediction of the IDH genotype.
Collapse
Affiliation(s)
- Philipp Lohmann
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany.
- Dept. of Stereotaxy and Functional Neurosurgery, University of Cologne, Cologne, Germany.
| | - Christoph Lerche
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany
| | - Elena K Bauer
- Dept. of Neurology, University of Cologne, Cologne, Germany
| | - Jan Steger
- Dept. of Neurology, University of Cologne, Cologne, Germany
| | - Gabriele Stoffels
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany
| | - Tobias Blau
- Dept. of Neuropathology, University of Cologne, Cologne, Germany
| | - Veronika Dunkl
- Dept. of Neurology, University of Cologne, Cologne, Germany
| | - Martin Kocher
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany
- Dept. of Stereotaxy and Functional Neurosurgery, University of Cologne, Cologne, Germany
| | - Shivakumar Viswanathan
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany
| | - Christian P Filss
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany
| | - Carina Stegmayr
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany
| | - Maximillian I Ruge
- Dept. of Stereotaxy and Functional Neurosurgery, University of Cologne, Cologne, Germany
| | - Bernd Neumaier
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany
| | - Nadim J Shah
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany
- Dept. of Neurology, University Hospital RWTH Aachen, Aachen, Germany
| | - Gereon R Fink
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany
- Dept. of Neurology, University of Cologne, Cologne, Germany
| | - Karl-Josef Langen
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany
- Dept. of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany
| | - Norbert Galldiks
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany
- Dept. of Neurology, University of Cologne, Cologne, Germany
- Center of Integrated Oncology (CIO), Universities of Cologne and Bonn, Cologne, Germany
| |
Collapse
|
102
|
Zeng J, Guareschi R, Damre M, Cao R, Kless A, Neumaier B, Bauer A, Giorgetti A, Carloni P, Rossetti G. Structural Prediction of the Dimeric Form of the Mammalian Translocator Membrane Protein TSPO: A Key Target for Brain Diagnostics. Int J Mol Sci 2018; 19:E2588. [PMID: 30200318 PMCID: PMC6165245 DOI: 10.3390/ijms19092588] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2018] [Revised: 08/21/2018] [Accepted: 08/28/2018] [Indexed: 11/17/2022] Open
Abstract
Positron emission tomography (PET) radioligands targeting the human translocator membrane protein (TSPO) are broadly used for the investigations of neuroinflammatory conditions associated with neurological disorders. Structural information on the mammalian protein homodimers-the suggested functional state of the protein-is limited to a solid-state nuclear magnetic resonance (NMR) study and to a model based on the previously-deposited solution NMR structure of the monomeric mouse protein. Computational studies performed here suggest that the NMR-solved structure in the presence of detergents is not prone to dimer formation and is furthermore unstable in its native membrane environment. We, therefore, propose a new model of the functionally-relevant dimeric form of the mouse protein, based on a prokaryotic homologue. The model, fully consistent with solid-state NMR data, is very different from the previous predictions. Hence, it provides, for the first time, structural insights into this pharmaceutically-important target which are fully consistent with experimental data.
Collapse
Affiliation(s)
- Juan Zeng
- Institute for Advanced Simulations (IAS)-5/Institute for Neuroscience and Medicine (INM)-9, Forschungszentrum Jülich, 52428 Jülich, Germany.
- Laboratory of Computational Chemistry and Drug Design, Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, 518055 Shenzhen, China.
| | - Riccardo Guareschi
- Institute for Advanced Simulations (IAS)-5/Institute for Neuroscience and Medicine (INM)-9, Forschungszentrum Jülich, 52428 Jülich, Germany.
| | - Mangesh Damre
- Department of Biotechnology, University of Verona, Strada Le Grazie 15, 37134 Verona, Italy.
- Neurobiology, International School for Advanced Studies (SISSA), 34136 Trieste, Italy.
| | - Ruyin Cao
- Institute for Advanced Simulations (IAS)-5/Institute for Neuroscience and Medicine (INM)-9, Forschungszentrum Jülich, 52428 Jülich, Germany.
| | - Achim Kless
- Grünenthal Innovation, Translational Science & Intelligence, Grünenthal GmbH, 52078 Aachen, Germany.
| | - Bernd Neumaier
- Institute for Neuroscience and Medicine (INM)-5, Forschungszentrum Jülich, 52428 Jülich, Germany.
| | - Andreas Bauer
- Institute for Neuroscience and Medicine (INM)-2, Forschungszentrum Jülich, 52428 Jülich, Germany.
| | - Alejandro Giorgetti
- Institute for Advanced Simulations (IAS)-5/Institute for Neuroscience and Medicine (INM)-9, Forschungszentrum Jülich, 52428 Jülich, Germany.
- Department of Biotechnology, University of Verona, Strada Le Grazie 15, 37134 Verona, Italy.
| | - Paolo Carloni
- Institute for Advanced Simulations (IAS)-5/Institute for Neuroscience and Medicine (INM)-9, Forschungszentrum Jülich, 52428 Jülich, Germany.
- RWTH Aachen University, Department of Physics, 52078 Aachen, Germany.
| | - Giulia Rossetti
- Institute for Advanced Simulations (IAS)-5/Institute for Neuroscience and Medicine (INM)-9, Forschungszentrum Jülich, 52428 Jülich, Germany.
- Jülich Supercomputing Center (JSC), Forschungszentrum Jülich, 52428 Jülich, Germany.
- University Hospital Aachen, RWTH Aachen University, 52078 Aachen, Germany.
| |
Collapse
|
103
|
Lohmann P, Kocher M, Ceccon G, Bauer EK, Stoffels G, Viswanathan S, Ruge MI, Neumaier B, Shah NJ, Fink GR, Langen KJ, Galldiks N. Combined FET PET/MRI radiomics differentiates radiation injury from recurrent brain metastasis. Neuroimage Clin 2018; 20:537-542. [PMID: 30175040 PMCID: PMC6118093 DOI: 10.1016/j.nicl.2018.08.024] [Citation(s) in RCA: 94] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/30/2018] [Revised: 08/01/2018] [Accepted: 08/17/2018] [Indexed: 12/12/2022]
Abstract
Background The aim of this study was to investigate the potential of combined textural feature analysis of contrast-enhanced MRI (CE-MRI) and static O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET for the differentiation between local recurrent brain metastasis and radiation injury since CE-MRI often remains inconclusive. Methods Fifty-two patients with new or progressive contrast-enhancing brain lesions on MRI after radiotherapy (predominantly stereotactic radiosurgery) of brain metastases were additionally investigated using FET PET. Based on histology (n = 19) or clinicoradiological follow-up (n = 33), local recurrent brain metastases were diagnosed in 21 patients (40%) and radiation injury in 31 patients (60%). Forty-two textural features were calculated on both unfiltered and filtered CE-MRI and summed FET PET images (20–40 min p.i.), using the software LIFEx. After feature selection, logistic regression models using a maximum of five features to avoid overfitting were calculated for each imaging modality separately and for the combined FET PET/MRI features. The resulting models were validated using cross-validation. Diagnostic accuracies were calculated for each imaging modality separately as well as for the combined model. Results For the differentiation between radiation injury and recurrence of brain metastasis, textural features extracted from CE-MRI had a diagnostic accuracy of 81% (sensitivity, 67%; specificity, 90%). FET PET textural features revealed a slightly higher diagnostic accuracy of 83% (sensitivity, 88%; specificity, 75%). However, the highest diagnostic accuracy was obtained when combining CE-MRI and FET PET features (accuracy, 89%; sensitivity, 85%; specificity, 96%). Conclusions Our findings suggest that combined FET PET/CE-MRI radiomics using textural feature analysis offers a great potential to contribute significantly to the management of patients with brain metastases. Differentiation between brain metastasis recurrence and radiation injury is of high clinical importance. Differentiation based on contrast-enhanced conventional MRI is often inconclusive. Radiomics and hybrid amino acid PET/MR imaging are increasingly gaining attention in Neuro-Oncology. We investigated the potential of combined PET/MRI radiomics analysis using MRI and FET PET in patients with brain metastases. Combined PET/MRI radiomics allows the differentiation of brain metastasis recurrence from radiation injury with high accuracy.
Collapse
Affiliation(s)
- Philipp Lohmann
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany; Dept. of Stereotaxy and Functional Neurosurgery, University of Cologne, Cologne, Germany.
| | - Martin Kocher
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany; Dept. of Stereotaxy and Functional Neurosurgery, University of Cologne, Cologne, Germany
| | - Garry Ceccon
- Dept. of Neurology, University of Cologne, Cologne, Germany
| | - Elena K Bauer
- Dept. of Neurology, University of Cologne, Cologne, Germany
| | - Gabriele Stoffels
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany
| | - Shivakumar Viswanathan
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany
| | - Maximilian I Ruge
- Dept. of Stereotaxy and Functional Neurosurgery, University of Cologne, Cologne, Germany
| | - Bernd Neumaier
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany
| | - Nadim J Shah
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany; Dept. of Neurology, University Hospital RWTH Aachen, Aachen, Germany
| | - Gereon R Fink
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany; Dept. of Neurology, University of Cologne, Cologne, Germany
| | - Karl-Josef Langen
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany; Dept. of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany
| | - Norbert Galldiks
- Inst. of Neuroscience and Medicine (INM-3, -4, -5), Forschungszentrum Juelich, Juelich, Germany; Dept. of Neurology, University of Cologne, Cologne, Germany; Center of Integrated Oncology (CIO), Universities of Cologne and Bonn, Cologne, Germany
| |
Collapse
|
104
|
Gee A, Neumaier B. Heinz H. Coenen-A pioneer in the field of nuclear and radiochemistry. J Labelled Comp Radiopharm 2018; 61:122-123. [DOI: 10.1002/jlcr.3599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2017] [Accepted: 12/21/2017] [Indexed: 11/11/2022]
Affiliation(s)
| | - Bernd Neumaier
- Institute of Neuroscience and Medicine; INM-5: Nuclear Chemistry, Forschungszentrum Jülich GmbH; Jülich Germany
| |
Collapse
|
105
|
Dronse J, Fliessbach K, Bischof GN, von Reutern B, Faber J, Hammes J, Kuhnert G, Neumaier B, Onur OA, Kukolja J, van Eimeren T, Jessen F, Fink GR, Klockgether T, Drzezga A. In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease. J Alzheimers Dis 2018; 55:465-471. [PMID: 27802224 DOI: 10.3233/jad-160316] [Citation(s) in RCA: 78] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The clinical heterogeneity of Alzheimer's disease is not reflected in the rather diffuse cortical deposition of amyloid-β. We assessed the relationship between clinical symptoms, in vivo tau pathology, amyloid distribution, and hypometabolism in variants of Alzheimer's disease using novel multimodal PET imaging techniques. Tau pathology was primarily observed in brain regions related to clinical symptoms and overlapped with areas of hypometabolism. In contrast, amyloid-β deposition was diffusely distributed over the entire cortex. Tau PET imaging may thus serve as a valuable biomarker for the localization of neuronal injury in vivo and may help to validate atypical subtypes of Alzheimer's disease.
Collapse
Affiliation(s)
- Julian Dronse
- Department of Neurology, University Hospital Cologne, Cologne, Germany.,Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, Jülich, Germany
| | - Klaus Fliessbach
- Department of Psychiatry and Psychotherapy, University Hospital Bonn, Bonn, Germany.,German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
| | - Gérard N Bischof
- Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, Jülich, Germany.,Multimodal Neuroimaging Group, Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany
| | - Boris von Reutern
- Department of Neurology, University Hospital Cologne, Cologne, Germany.,Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, Jülich, Germany
| | - Jennifer Faber
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.,Department of Neurology, University Hospital Bonn, Bonn, Germany
| | - Jochen Hammes
- Multimodal Neuroimaging Group, Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany
| | - Georg Kuhnert
- Multimodal Neuroimaging Group, Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany
| | - Bernd Neumaier
- Nuclear Chemistry, Institute of Neuroscience and Medicine (INM-5), Research Center Jülich, Jülich, Germany.,Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital Cologne, Cologne, Germany
| | - Oezguer A Onur
- Department of Neurology, University Hospital Cologne, Cologne, Germany.,Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, Jülich, Germany
| | - Juraj Kukolja
- Department of Neurology, University Hospital Cologne, Cologne, Germany.,Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, Jülich, Germany
| | - Thilo van Eimeren
- Department of Neurology, University Hospital Cologne, Cologne, Germany.,Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, Jülich, Germany.,German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.,Multimodal Neuroimaging Group, Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany
| | - Frank Jessen
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.,Department of Psychiatry, University Hospital Cologne, Cologne, Germany
| | - Gereon R Fink
- Department of Neurology, University Hospital Cologne, Cologne, Germany.,Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, Jülich, Germany
| | - Thomas Klockgether
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.,Department of Neurology, University Hospital Bonn, Bonn, Germany
| | - Alexander Drzezga
- German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.,Multimodal Neuroimaging Group, Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany
| |
Collapse
|
106
|
Kull T, Blumstein NM, Bunjes D, Neumaier B, Buck AK, Reske SN, Glatting G. Dosimetry with 188Re-labelled monoclonal anti-CD66 antibodies. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1625927] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryAim: For the therapeutic application of radiopharmaceuticals the activity is determined on an individual basis. Here we investigated the accuracy for a simplified assessment of the residence times for a 188Re-labelled anti-CD66 monoclonal antibody. Patients, methods: For 49 patients with high risk leukaemia (24 men, 25 women, age: 44 ± 12 years) the residence times were determined for the injected 188Re-labelled anti-CD66 antibodies (1.3 ± 0.4 GBq, 5–7 GBq/mg protein, >95% 188Re bound to the antibody) based on 5 measurements (1.5, 3, 20, 26, and 44 h p.i.) using planar conjugate view gamma camera images (complete method). In a simplified method the residence times were calculated based on a single measurement 3 h p.i. Results: The residence times for kidneys, liver, red bone marrow, spleen and remainder of body for the complete method were 0.4 ± 0.2 h, 1.9 ± 0.8 h, 7.8 ± 2.1 h, 0.6 ± 0.3 h and 8.6 ± 2.1 h, respectively. For all organs a linear correlation exists between the residence times of the complete method and the simplified method with the slopes (correlation coefficients R > 0.89) of 0.89, 0.99, 1.23, 1.13 and 1.09 for kidneys, liver, red bone marrow, spleen and remainder of body, respectively. Conclusion: The proposed approach allows reliable prediction of biokinetics of 188Re-labelled anti-CD66 monoclonal antibody biodistribution with a single study. Efficient pretherapeutic estimation of organ absorbed dose may be possible, provided that a more stable anti-CD66 antibody preparation is available.
Collapse
|
107
|
Volkmer BG, Glatting G, van den Hoff J, Gschwend JE, Messer P, Reske SN, Neumaier B, Kotzerke J. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1623902] [Citation(s) in RCA: 57] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
AbstractIn a pilot trial we investigated whether significant differences in prostate cancer (PCA) imaging would be observed using [11C]acetate and [11C]choline positron emission tomography (PET). Methods: Twelve patients were studied with both radiotracers. Whole body PET without attenuation correction was performed after injection of 0.95 ± 0.15 GBq [11C]acetate and 0.84 ± 0.13 GBq [11C]choline, respectively, from 5 to 60 min p. i. Focally increased uptake in bone, below the urinary bladder or in a lymph node region was considered as tumour. Primary tumour, lymph node involvement, bone metastases, local recurrence; and no evidence of disease were known in 2, 4, 2, 2; and 2 patients, respectively. Results: [11C]Acetate uptake was highest in spleen and pancreas while [11C]choline uptake was predominant in liver and kidney parenchyma. However, interindividual variation was high. The potential of both radiotracers to detect known bone lesions, lymph node metastases, and imaging of the primary tumour was identical. However, both failed to detect a small local recurrence in two patients as well as to demonstrate lymph node involvement in one patient, which was confirmed by surgery. Conclusions: In this preliminary study, uptake of both radiotracers in prostate cancer or its metastases was nearly identical and none of them should be favoured. At present, both radiotracers influence patient management by detection of local recurrence, lymph node, or bone metastases of PCA.
Collapse
|
108
|
Hoenig MC, Bischof GN, Seemiller J, Hammes J, Kukolja J, Onur ÖA, Jessen F, Fliessbach K, Neumaier B, Fink GR, van Eimeren T, Drzezga A. Networks of tau distribution in Alzheimer’s disease. Brain 2018; 141:568-581. [DOI: 10.1093/brain/awx353] [Citation(s) in RCA: 94] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Accepted: 11/08/2017] [Indexed: 12/13/2022] Open
|
109
|
Thees S, Neumaier B, Deisenhofer S, von Arnim CAF, Reske SN, Mottaghy FM, Glatting G. Radiation dosimetry and biodistribution of the beta-amyloid plaque imaging tracer 11C-BTA-1 in humans. Nuklearmedizin 2017. [DOI: 10.1160/nukmed-0077] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
SummaryAim: [N-methyl-11C]2-(4'-(methylaminophenyl)-benzothiazole (11C-BTA-1) is a thioflavin-T derivative that has been one of the promising PET tracers for imaging of amyloid plaque distribution in the Alzheimer patients brain in vivo. The biodistribution and dosimetry of this tracer in humans is presented and compared to the results of a previous dosimetry and biodistribution study of another thioflavin-T derivative [N-methyl-11C]2-hydroxy-(4'-(methylaminophenyl)- benzothiazole (11C-OH-BTA-1) in baboons. Methods: Five subjects underwent 2D dynamic PET imaging. Source organs were segmented using a semiautomatic algorithm based on clustering. Residence times for each source organ were determined by analytical integration of an exponential fit of the time activity curves. Finally organ doses were estimated using the software OLINDA/EXM. Results: The administration of 286 ± 93 MBq 11C-BTA-1 was well tolerated by all subjects. Effective radiation dose was 4.3 μSv/MBq, range 3.6–5.0 μSv/MBq. In four of the five subjects the liver, in one of the subjects the gallbladder was the critical organ. Conclusion: The radiation burden of a single dose of 300 MBq 11C-BTA-1 is within the accepted limits for research purpose. In contrast to the previous non-human primate study revealing the gallbladder as the critical organ for 11C-6-OH-BTA-1, we found the liver as the critical organ in humans using 11C-BTA-1. Possible explanations may be (1) a reduced bile concentration of 11C-BTA-1 due to the absent OH-group or (2) a different hepatic metabolism of thioflavin derivatives in human and baboon.
Collapse
|
110
|
Zlatopolskiy BD, Zischler J, Schäfer D, Urusova EA, Guliyev M, Bannykh O, Endepols H, Neumaier B. Discovery of 7-[18F]Fluorotryptophan as a Novel Positron Emission Tomography (PET) Probe for the Visualization of Tryptophan Metabolism in Vivo. J Med Chem 2017; 61:189-206. [DOI: 10.1021/acs.jmedchem.7b01245] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Boris D. Zlatopolskiy
- Institute
of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Forschungszentrum Jülich GmbH, Jülich 52428, Germany
- Institute
of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, Cologne 50937, Germany
- Max Planck Institute for Metabolism Research, Cologne 50931, Germany
| | - Johannes Zischler
- Institute
of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Forschungszentrum Jülich GmbH, Jülich 52428, Germany
- Institute
of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, Cologne 50937, Germany
| | - Dominique Schäfer
- Institute
of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Forschungszentrum Jülich GmbH, Jülich 52428, Germany
| | - Elizaveta A. Urusova
- Institute
of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Forschungszentrum Jülich GmbH, Jülich 52428, Germany
- Institute
of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, Cologne 50937, Germany
- Max Planck Institute for Metabolism Research, Cologne 50931, Germany
| | - Mehrab Guliyev
- Institute
of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Forschungszentrum Jülich GmbH, Jülich 52428, Germany
- Institute
of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, Cologne 50937, Germany
| | - Olesia Bannykh
- Institute
of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Forschungszentrum Jülich GmbH, Jülich 52428, Germany
- Institute
of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, Cologne 50937, Germany
| | - Heike Endepols
- Institute
of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Forschungszentrum Jülich GmbH, Jülich 52428, Germany
- Institute
of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, Cologne 50937, Germany
- Max Planck Institute for Metabolism Research, Cologne 50931, Germany
- Department
of Nuclear Medicine, University Clinic Cologne, Cologne 50937, Germany
| | - Bernd Neumaier
- Institute
of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Forschungszentrum Jülich GmbH, Jülich 52428, Germany
- Institute
of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, Cologne 50937, Germany
- Max Planck Institute for Metabolism Research, Cologne 50931, Germany
| |
Collapse
|
111
|
Lohmann P, Lerche C, Bauer E, Steger J, Stoffels G, Blau T, Dunkl V, Filss CP, Stegmayr C, Neumaier B, Shah NJ, Fink G, Langen KJ, Galldiks N. NIMG-32. DIFFERENTIATION OF PSEUDOPROGRESSION FROM TUMOR PROGRESSION IN GLIOBLASTOMA PATIENTS BASED ON FET PET RADIOMICS. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.607] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
112
|
Lohmann P, Lerche C, Bauer E, Steger J, Stoffels G, Blau T, Dunkl V, Filss CP, Stegmayr C, Neumaier B, Shah NJ, Fink G, Langen KJ, Galldiks N. NIMG-82. PREDICTING ISOCITRATE DEHYDROGENASE GENOTYPE IN GLIOMAS USING FET PET RADIOMICS. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.652] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
113
|
Verger A, Stoffels G, Bauer EK, Lohmann P, Blau T, Fink GR, Neumaier B, Shah NJ, Langen KJ, Galldiks N. Static and dynamic 18F–FET PET for the characterization of gliomas defined by IDH and 1p/19q status. Eur J Nucl Med Mol Imaging 2017; 45:443-451. [DOI: 10.1007/s00259-017-3846-6] [Citation(s) in RCA: 63] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2017] [Accepted: 10/02/2017] [Indexed: 01/01/2023]
|
114
|
Morgenroth A, Vogg ATJ, Neumaier B, Mottaghy FM, Zlatopolskiy BD. Radioiodinated indomethacin amide for molecular imaging of cyclooxygenase-2 expressing tumors. Oncotarget 2017; 8:18059-18069. [PMID: 28407689 PMCID: PMC5392307 DOI: 10.18632/oncotarget.15437] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Accepted: 01/27/2017] [Indexed: 12/18/2022] Open
Abstract
Cyclooxygenase-2 (COX-2) is an important biomarker in several tumors. Available imaging probes display relatively low tumor to background ratios (smaller than 2:1). We evaluated newly developed indomethacin (Ind) derivatives for in vivo molecular imaging of COX-2 expressing carcinoma. Radioiodinated Ind derivatives Ind-NH-(CH2)4-NH-3-[I-125]I-Bz ([I-125]5), Ind-NH-(CH2)4-NH-5-[I-124/125]I-Nic ([I-124/125]6) and Ind-NH-(CH2)4-NH-5-[I-125]I-Iphth ([I-125]7) were prepared from the respective SnBu3-precursors (45-80% radiochemical yield; > 95% radiochemical purity). The cellular uptake of [I-125]5 and [I-125]6 correlated with COX-2 expression determined by SDS page/Western blot analysis. [I-125]5 was predominantly localized in the cell membrane while [I-125]6 was internalized and displayed a diffuse and favorable cytoplasmic distribution. In contrast, [I-125]7 showed only low uptake in COX-2 positive cells. Co-incubation with the COX-2 inhibitor Celecoxib led to an almost complete suppression of cellular uptake of [I-125]5 and [I-125]6. In vivo molecular imaging using positron emission tomography (PET) in SCID mice xenografted with COX-2+ (HT29) and COX-2- (HCT116) human colorectal carcinoma cells was performed for [I-124]6. HT29 xenografts displayed a significantly higher uptake than HCT-116 xenografts (5.6 ± 1.5 vs. 0.5 ± 0.1 kBq/g, P < 0.05) with an extraordinary high tumor to muscle ratio (50.3 ± 1.5). Immunohistological staining correlated with the imaging data. In conclusion, the novel radioiodinated indomethacin derivative ([I-124/125]6) could become a valuable tool for development of molecular imaging probes for visualization of COX-2 expressing tumors.
Collapse
Affiliation(s)
- Agnieszka Morgenroth
- Department for Nuclear Medicine, RWTH Aachen University Hospital, 52074, Aachen, Germany
| | - Andreas T J Vogg
- Department for Nuclear Medicine, RWTH Aachen University Hospital, 52074, Aachen, Germany
| | - Bernd Neumaier
- Institute of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, 50937, Cologne, Germany.,Max Planck Institute of Metabolism Research, 50931, Cologne, Germany.,Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Research Center Jülich, 52425, Jülich, Germany
| | - Felix M Mottaghy
- Department for Nuclear Medicine, RWTH Aachen University Hospital, 52074, Aachen, Germany.,Department of Nuclear Medicine, Maastricht University Medical Center, 6229 HX, Maastricht, The Netherlands
| | - Boris D Zlatopolskiy
- Department for Nuclear Medicine, RWTH Aachen University Hospital, 52074, Aachen, Germany.,Institute of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, 50937, Cologne, Germany.,Max Planck Institute of Metabolism Research, 50931, Cologne, Germany
| |
Collapse
|
115
|
Kordys E, Apetz N, Schneider K, Duncan E, Büschbell B, Rohleder C, Sué M, Drzezga A, Neumaier B, Timmermann L, Endepols H. Motor impairment and compensation in a hemiparkinsonian rat model: correlation between dopamine depletion severity, cerebral metabolism and gait patterns. EJNMMI Res 2017; 7:68. [PMID: 28831764 PMCID: PMC5567589 DOI: 10.1186/s13550-017-0317-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2017] [Accepted: 08/16/2017] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND In Parkinson's disease (PD), cerebral dopamine depletion is associated with PD subtype-specific metabolic patterns of hypo- and hypermetabolism. It has been hypothesised that hypometabolism reflects impairment, while hypermetabolism may indicate compensatory activity. In order to associate metabolic patterns with pathophysiological and compensatory mechanisms, we combined resting state [18F]FDG-PET (to demonstrate brain metabolism in awake animals), [18F]FDOPA-PET (dopamine depletion severity) and gait analysis in a unilateral 6-hydroxydopamine rat model. RESULTS We found unilateral nigro-striatal dopaminergic loss to decrease swing speed of the contralesional forelimb and stride length of all paws in association with depletion severity. Depletion severity was found to correlate with compensatory changes such as increased stance time of the other three paws and diagonal weight shift to the ipsilesional hind paw. [18F]FDG-PET revealed ipsilesional hypo- and contralesional hypermetabolism; metabolic deactivation of the ipsilesional network needed for sensorimotor integration (hippocampus/retrosplenial cortex/lateral posterior thalamus) was solely associated with bradykinesia, but hypometabolism of the ipsilesional rostral forelimb area was related to both pathological and compensatory gait changes. Mixed effects were also found for hypermetabolism of the contralesional midbrain locomotor region, while contralesional striatal hyperactivation was linked to motor impairments rather than compensation. CONCLUSIONS Our results indicate that ipsilesional hypo- and contralesional hypermetabolism contribute to both motor impairment and compensation. This is the first time when energy metabolism, dopamine depletion and gait analysis were combined in a hemiparkinsonian model. By experimentally increasing or decreasing compensational brain activity, its potential and limits can be further investigated.
Collapse
Affiliation(s)
- Elena Kordys
- Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Kerpener Str. 62, 50937, Köln, Germany
| | - Nadine Apetz
- Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Kerpener Str. 62, 50937, Köln, Germany.,Department of Neurology, University Hospital of Cologne, Kerpener Str. 62, 50937, Köln, Germany
| | - Katharina Schneider
- Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Kerpener Str. 62, 50937, Köln, Germany
| | - Eilidh Duncan
- Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Kerpener Str. 62, 50937, Köln, Germany
| | - Beatriz Büschbell
- Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Kerpener Str. 62, 50937, Köln, Germany
| | - Cathrin Rohleder
- Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Kerpener Str. 62, 50937, Köln, Germany.,Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, J5, 68159, Mannheim, Germany
| | - Michael Sué
- Max-Planck Institute of Metabolism Research, Gleueler Str. 50, 50931, Köln, Germany
| | - Alexander Drzezga
- Department of Nuclear Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Köln, Germany
| | - Bernd Neumaier
- Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Kerpener Str. 62, 50937, Köln, Germany.,Forschungszentrum Jülich GmbH, Institute for Neuroscience and Medicine, INM-5: Nuclear Chemistry, 52425, Jülich, Germany
| | - Lars Timmermann
- Department of Neurology, University Hospital of Cologne, Kerpener Str. 62, 50937, Köln, Germany
| | - Heike Endepols
- Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Kerpener Str. 62, 50937, Köln, Germany. .,Department of Nuclear Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Köln, Germany.
| |
Collapse
|
116
|
Vanasschen C, Molnár E, Tircsó G, Kálmán FK, Tóth É, Brandt M, Coenen HH, Neumaier B. Novel CDTA-based, Bifunctional Chelators for Stable and Inert MnII Complexation: Synthesis and Physicochemical Characterization. Inorg Chem 2017. [DOI: 10.1021/acs.inorgchem.7b00460] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Christian Vanasschen
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich GmbH, Jülich, Germany
| | - Enikő Molnár
- Department of Inorganic and Analytical Chemistry, Faculty
of Science and Technology, University of Debrecen, Debrecen, Egyetem tér 1, H-4010, Hungary
| | - Gyula Tircsó
- Department of Inorganic and Analytical Chemistry, Faculty
of Science and Technology, University of Debrecen, Debrecen, Egyetem tér 1, H-4010, Hungary
| | - Ferenc K. Kálmán
- Department of Inorganic and Analytical Chemistry, Faculty
of Science and Technology, University of Debrecen, Debrecen, Egyetem tér 1, H-4010, Hungary
- Centre de Biophysique Moléculaire,
CNRS, Université d’Orléans, rue Charles Sadron, 45071 Orléans, Cedex 2, France
- Le Studium, Loire Valley Institute for Advanced Studies, 1 Rue
Dupanloup, 45000 Orléans, France
| | - Éva Tóth
- Centre de Biophysique Moléculaire,
CNRS, Université d’Orléans, rue Charles Sadron, 45071 Orléans, Cedex 2, France
| | - Marie Brandt
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich GmbH, Jülich, Germany
| | - Heinz H. Coenen
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich GmbH, Jülich, Germany
| | - Bernd Neumaier
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich GmbH, Jülich, Germany
| |
Collapse
|
117
|
Holschbach MH, Bier D, Sihver W, Schulze A, Neumaier B. Synthesis and Pharmacological Evaluation of Identified and Putative Metabolites of the A 1 Adenosine Receptor Antagonist 8-Cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine (CPFPX). ChemMedChem 2017; 12:770-784. [PMID: 28217962 DOI: 10.1002/cmdc.201600592] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2016] [Revised: 02/15/2017] [Indexed: 11/09/2022]
Abstract
The A1 adenosine receptor (A1 AR) antagonist [18 F]8-cyclopentyl-3-(3-fluoropropyl)-1-propylxanthine ([18 F]CPFPX), used in imaging human brain A1 ARs by positron emission tomography (PET), is stable in the brain, but rapidly undergoes transformation into one major (3-(3-fluoropropyl)-8-(3-oxocyclopenten-1-yl)-1-propylxanthine, M1) and several minor metabolites in blood. This report describes the synthesis of putative metabolites of CPFPX as standards for the identification of those metabolites. Analysis by (radio)HPLC revealed that extracts of human liver microsomes incubated with no-carrier-added (n.c.a.)[18 F]CPFPX contain the major metabolite, M1, as well as radioactive metabolites corresponding to derivatives functionalized at the cyclopentyl moiety, but no N1-despropyl species or metabolites resulting from functionalization of the N3-fluoropropyl chain. The putative metabolites were found to displace the binding of [3 H]CPFPX to the A1 AR in pig brain cortex at Ki values between 1.9 and 380 nm and the binding of [3 H]ZM241385 to the A2A AR in pig striatum at Ki values >180 nm. One metabolite, a derivative functionalized at the ω-position of the N1-propyl chain, showed high affinity (Ki 2 nm) to and very good selectivity (>9000) for the A1 AR.
Collapse
Affiliation(s)
- Marcus H Holschbach
- Institut für Neurowissenschaften und Medizin-Nuklearchemie, INM-5, Forschungszentrum Jülich GmbH, Wilhelm-Johnen-Straße, 52428, Jülich, Germany
| | - Dirk Bier
- Institut für Neurowissenschaften und Medizin-Nuklearchemie, INM-5, Forschungszentrum Jülich GmbH, Wilhelm-Johnen-Straße, 52428, Jülich, Germany
| | - Wiebke Sihver
- Institut für Radiopharmazeutische Krebsforschung, Helmholtz-Zentrum Dresden-Rossendorf, Bautzener Landstraße 400, 01328, Dresden, Germany
| | - Annette Schulze
- Institut für Neurowissenschaften und Medizin-Nuklearchemie, INM-5, Forschungszentrum Jülich GmbH, Wilhelm-Johnen-Straße, 52428, Jülich, Germany
| | - Bernd Neumaier
- Institut für Neurowissenschaften und Medizin-Nuklearchemie, INM-5, Forschungszentrum Jülich GmbH, Wilhelm-Johnen-Straße, 52428, Jülich, Germany
| |
Collapse
|
118
|
Rowe SP, Drzezga A, Neumaier B, Dietlein M, Gorin MA, Zalutsky MR, Pomper MG. Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. J Nucl Med 2017; 57:90S-96S. [PMID: 27694179 DOI: 10.2967/jnumed.115.170175] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2016] [Accepted: 08/08/2016] [Indexed: 12/16/2022] Open
Abstract
Radiohalogenated agents are often the first line of pursuit in the development of new radiopharmaceuticals-whether antibodies, peptides, or small molecules-because of their ease of synthesis, lack of substantial steric perturbation of the original affinity agent (in some cases, providing enhanced affinity), and capacity to be transformed into therapeutics (in some cases, with a mere switch of an isotope). They often provide proof of a principle before optimization for pharmacokinetics or generation of radiometallated agents, when the latter are necessary. In particular, 18F has been well integrated into normal clinical work flow in the form of 18F-FDG for oncologic imaging, with reliable daily production and distribution to sites for immediate use, without the need for on-site preparation. Here we discuss radiohalogenated versions of imaging and therapeutic agents targeting the prostate-specific membrane antigen (PSMA); these were among the first such agents to be synthesized and used clinically. PSMA is highly expressed on prostate cancer epithelial cells and is currently being extensively investigated around the world as a target for imaging and therapy of prostate cancer. Additionally, the presence of PSMA on nonprostate tumor neovasculature has opened the possibility of PSMA-targeted molecules as generalizable cancer imaging and therapy agents. We focus on 18F-labeled agents for PET, as they begin to redefine-along with the corresponding 68Ga-labeled agents discussed elsewhere in this supplement to The Journal of Nuclear Medicine-the management of prostate cancer across a variety of clinical contexts.
Collapse
Affiliation(s)
- Steven P Rowe
- The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Alexander Drzezga
- Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany
| | - Bernd Neumaier
- Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Cologne, Germany
| | - Markus Dietlein
- Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany
| | - Michael A Gorin
- The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland; and
| | - Michael R Zalutsky
- Department of Radiology, Duke University Medical Center, Durham, North Carolina
| | - Martin G Pomper
- The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland
| |
Collapse
|
119
|
Oláh Z, Kremmer T, Vogg A, Varga Z, Szűcs Z, Neumaier B, Dóczi R. Novel ion exchange chromatography method for nca arsenic separation. Appl Radiat Isot 2017; 122:111-115. [DOI: 10.1016/j.apradiso.2017.01.008] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2016] [Revised: 12/15/2016] [Accepted: 01/13/2017] [Indexed: 11/30/2022]
|
120
|
Lohmann P, Lerche C, Bauer E, Steger J, Stoffels G, Filss CP, Stegmayr C, Neumaier B, Shah NJ, Langen K, Galldiks N. P10.17 Predicting isocitrate dehydrogenase genotype in malignant glioma using FET PET radiomics. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
121
|
Lohmann P, Lerche C, Stoffels G, Filss CP, Stegmayr C, Neumaier B, Shah NJ, Langen K, Galldiks N. P09.26 FET PET radiomics - diagnosis of pseudoprogression in glioblastoma patients based on textural features. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.282] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
122
|
Zischler J, Kolks N, Modemann D, Neumaier B, Zlatopolskiy BD. Back Cover: Alcohol-Enhanced Cu-Mediated Radiofluorination (Chem. Eur. J. 14/2017). Chemistry 2017. [DOI: 10.1002/chem.201700191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Johannes Zischler
- Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry; Forschungszentrum Jülich GmbH; 52425 Jülich Germany
- Institute of Radiochemistry and Experimental Molecular Imaging; University Clinic Cologne; Kerpener Str. 62 50937 Cologne Germany
- Max Planck Institute for Metabolism Research; Gleueler Str. 50 50931 Cologne Germany
| | - Niklas Kolks
- Institute of Radiochemistry and Experimental Molecular Imaging; University Clinic Cologne; Kerpener Str. 62 50937 Cologne Germany
| | - Daniel Modemann
- Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry; Forschungszentrum Jülich GmbH; 52425 Jülich Germany
| | - Bernd Neumaier
- Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry; Forschungszentrum Jülich GmbH; 52425 Jülich Germany
- Institute of Radiochemistry and Experimental Molecular Imaging; University Clinic Cologne; Kerpener Str. 62 50937 Cologne Germany
- Max Planck Institute for Metabolism Research; Gleueler Str. 50 50931 Cologne Germany
| | - Boris D. Zlatopolskiy
- Institute of Radiochemistry and Experimental Molecular Imaging; University Clinic Cologne; Kerpener Str. 62 50937 Cologne Germany
- Max Planck Institute for Metabolism Research; Gleueler Str. 50 50931 Cologne Germany
| |
Collapse
|
123
|
Zischler J, Kolks N, Modemann D, Neumaier B, Zlatopolskiy BD. Alcohol-Enhanced Cu-Mediated Radiofluorination. Chemistry 2017; 23:3251-3256. [DOI: 10.1002/chem.201604633] [Citation(s) in RCA: 83] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Indexed: 02/01/2023]
Affiliation(s)
- Johannes Zischler
- Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry; Forschungszentrum Jülich GmbH; 52425 Jülich Germany
- Institute of Radiochemistry and Experimental Molecular Imaging; University Clinic Cologne; Kerpener Str. 62 50937 Cologne Germany
- Max Planck Institute for Metabolism Research; Gleueler Str. 50 50931 Cologne Germany
| | - Niklas Kolks
- Institute of Radiochemistry and Experimental Molecular Imaging; University Clinic Cologne; Kerpener Str. 62 50937 Cologne Germany
| | - Daniel Modemann
- Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry; Forschungszentrum Jülich GmbH; 52425 Jülich Germany
| | - Bernd Neumaier
- Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry; Forschungszentrum Jülich GmbH; 52425 Jülich Germany
- Institute of Radiochemistry and Experimental Molecular Imaging; University Clinic Cologne; Kerpener Str. 62 50937 Cologne Germany
- Max Planck Institute for Metabolism Research; Gleueler Str. 50 50931 Cologne Germany
| | - Boris D. Zlatopolskiy
- Institute of Radiochemistry and Experimental Molecular Imaging; University Clinic Cologne; Kerpener Str. 62 50937 Cologne Germany
- Max Planck Institute for Metabolism Research; Gleueler Str. 50 50931 Cologne Germany
| |
Collapse
|
124
|
Breunig K, Scholten B, Spahn I, Hermanne A, Spellerberg S, Coenen HH, Neumaier B. Production of medically useful bromine isotopes via alpha-particle induced nuclear reactions. EPJ Web Conf 2017. [DOI: 10.1051/epjconf/201714608006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
125
|
Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, Schomäcker K, Heidenreich A, Zlatopolskiy BD, Neumaier B, Drzezga A, Dietlein M. PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. J Nucl Med 2016; 58:947-952. [PMID: 27908968 DOI: 10.2967/jnumed.116.185538] [Citation(s) in RCA: 130] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Accepted: 11/25/2016] [Indexed: 11/16/2022] Open
Abstract
Several studies outlined the sensitivity of 68Ga-labeled PET tracers against the prostate-specific membrane antigen (PSMA) for localization of relapsed prostate cancer in patients with renewed increase in the prostate-specific antigen (PSA), commonly referred to as biochemical recurrence. Labeling of PSMA tracers with 18F offers numerous advantages, including improved image resolution, longer half-life, and increased production yields. The aim of this study was to assess the PSA-stratified performance of the 18F-labeled PSMA tracer 18F-DCFPyL and the 68Ga-labeled reference 68Ga-PSMA-HBED-CC. Methods: We examined 191 consecutive patients with biochemical recurrence according to standard acquisition protocols using 18F-DCFPyL (n = 62, 269.8 MBq, PET scan at 120 min after injection) or 68Ga-PSMA-HBED-CC (n = 129, 158.9 MBq, 60 min after injection). We determined PSA-stratified sensitivity rates for both tracers and corrected our calculations for Gleason scores using iterative matched-pair analyses. As an orthogonal validation, we directly compared tracer distribution patterns in a separate cohort of 25 patients, sequentially examined with both tracers. Results: After prostatectomy (n = 106), the sensitivity of both tracers was significantly associated with absolute PSA levels (P = 4.3 × 10-3). Sensitivity increased abruptly, when PSA values exceeded 0.5 μg/L (P = 2.4 × 10-5). For a PSA less than 3.5 μg/L, most relapses were diagnosed at a still limited stage (P = 3.4 × 10-6). For a PSA of 0.5-3.5 μg/L, PSA-stratified sensitivity was 88% (15/17) for 18F-DCFPyL and 66% (23/35) for 68Ga-PSMA-HBED-CC. This significant difference was preserved in the Gleason-matched-pair analysis. Outside of this range, sensitivity was comparably low (PSA < 0.5 μg/L) or high (PSA > 3.5 μg/L). After radiotherapy (n = 85), tracer sensitivity was largely PSA-independent. In the 25 patients examined with both tracers, distribution patterns of 18F-DCFPyL and 68Ga-PSMA-HBED-CC were strongly comparable (P = 2.71 × 10-8). However, in 36% of the PSMA-positive patients we detected additional lesions on the 18F-DCFPyL scan (P = 3.7 × 10-2). Conclusion: Our data suggest that 18F-DCFPyL is noninferior to 68Ga-PSMA-HBED-CC, while offering the advantages of 18F labeling. Our results indicate that imaging with 18F-DCFPyL may even exhibit improved sensitivity in localizing relapsed tumors after prostatectomy for moderately increased PSA levels. Although the standard acquisition protocols, used for 18F-DCFPyL and 68Ga-PSMA-HBED-CC in this study, stipulate different activity doses and tracer uptake times after injection, our findings provide a promising rationale for validation of 18F-DCFPyL in future prospective trials.
Collapse
Affiliation(s)
- Felix Dietlein
- Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany .,Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany
| | - Carsten Kobe
- Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.,Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany
| | | | - Matthias Schmidt
- Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.,Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany
| | - Simone Stockter
- Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany
| | - Thomas Fischer
- Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany
| | - Klaus Schomäcker
- Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany
| | - Axel Heidenreich
- Department of Urology, University Hospital of Cologne, Cologne, Germany; and
| | - Boris D Zlatopolskiy
- Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Cologne, Germany
| | - Bernd Neumaier
- Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Cologne, Germany
| | - Alexander Drzezga
- Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.,Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany
| | - Markus Dietlein
- Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.,Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany
| |
Collapse
|
126
|
Bischof GN, Jessen F, Fliessbach K, Dronse J, Hammes J, Neumaier B, Onur O, Fink GR, Kukolja J, Drzezga A, van Eimeren T. Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease. Ann Clin Transl Neurol 2016; 3:934-939. [PMID: 28097205 PMCID: PMC5224823 DOI: 10.1002/acn3.339] [Citation(s) in RCA: 74] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Accepted: 07/18/2016] [Indexed: 01/21/2023] Open
Abstract
In a multimodal PET imaging approach, we determined the differential contribution of neurofibrillary tangles (measured with [18F]AV‐1451) and beta‐amyloid burden (measured with [11C]PiB) on degree of neurodegeneration (i.e., glucose metabolism measured with [18F]FDG‐PET) in patients with Alzheimer's disease. Across brain regions, we observed an interactive effect of beta‐amyloid burden and tau deposition on glucose metabolism which was most pronounced in the parietal lobe. Elevated beta‐amyloid burden was associated with a stronger influence of tau accumulation on glucose metabolism. Our data provide the first in vivo insights into the differential contribution of Aβ and tau to neurodegeneration in Alzheimer's disease.
Collapse
Affiliation(s)
- Gérard N Bischof
- Multimodal Neuroimaging Group Department of Nuclear Medicine University Hospital Cologne Cologne Germany; Cognitive Neuroscience Institute of Neuroscience and Medicine (INM-3)Research Center Jülich Jülich Germany
| | - Frank Jessen
- German Center for Neurodegenerative Diseases (DZNE) Bonn Germany; Department of Psychiatry University Hospital Cologne Cologne Germany
| | - Klaus Fliessbach
- German Center for Neurodegenerative Diseases (DZNE) Bonn Germany; Department of Psychiatry and Psychotherapy University Hospital Bonn Bonn Germany
| | - Julian Dronse
- Cognitive Neuroscience Institute of Neuroscience and Medicine (INM-3)Research Center Jülich Jülich Germany; Department of Neurology University Hospital Cologne Cologne Germany
| | - Jochen Hammes
- Multimodal Neuroimaging Group Department of Nuclear Medicine University Hospital Cologne Cologne Germany
| | - Bernd Neumaier
- Institute of Radiochemistry and Experimental Molecular Imaging University of Cologne Cologne Germany; Institute of Neuroscience & Medicine (INM-5)Nuclear Chemistry Research Center Jülich Jülich Germany
| | - Oezguer Onur
- Cognitive Neuroscience Institute of Neuroscience and Medicine (INM-3)Research Center Jülich Jülich Germany; Department of Neurology University Hospital Cologne Cologne Germany
| | - Gereon R Fink
- Cognitive Neuroscience Institute of Neuroscience and Medicine (INM-3)Research Center Jülich Jülich Germany; Department of Neurology University Hospital Cologne Cologne Germany
| | - Juraj Kukolja
- Cognitive Neuroscience Institute of Neuroscience and Medicine (INM-3)Research Center Jülich Jülich Germany; Department of Neurology University Hospital Cologne Cologne Germany
| | - Alexander Drzezga
- Multimodal Neuroimaging Group Department of Nuclear Medicine University Hospital Cologne Cologne Germany; German Center for Neurodegenerative Diseases (DZNE) Bonn Germany
| | - Thilo van Eimeren
- Multimodal Neuroimaging Group Department of Nuclear Medicine University Hospital Cologne Cologne Germany; Cognitive Neuroscience Institute of Neuroscience and Medicine (INM-3)Research Center Jülich Jülich Germany; German Center for Neurodegenerative Diseases (DZNE) Bonn Germany; Department of Neurology University Hospital Cologne Cologne Germany
| | | |
Collapse
|
127
|
Zischler J, Krapf P, Richarz R, Zlatopolskiy BD, Neumaier B. Automated synthesis of 4-[18F]fluoroanisole, [18F]DAA1106 and 4-[18F]FPhe using Cu-mediated radiofluorination under “minimalist” conditions. Appl Radiat Isot 2016; 115:133-137. [DOI: 10.1016/j.apradiso.2016.04.030] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Revised: 04/14/2016] [Accepted: 04/27/2016] [Indexed: 10/21/2022]
|
128
|
Reetz K, Giehl K, Dogan I, Werner CJ, Hammes J, Schulz JB, Neumaier B, Drzezga A, Eimeren TV. D26 Pathological tau signal in huntington’s disease – an in vivo [18F]-AV-1451 pet imaging report. J Neurol Psychiatry 2016. [DOI: 10.1136/jnnp-2016-314597.125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
129
|
Schäfer D, Weiß P, Ermert J, Castillo Meleán J, Zarrad F, Neumaier B. Preparation of No-Carrier-Added 6-[18F]Fluoro-l-tryptophan via Cu-Mediated Radiofluorination. European J Org Chem 2016. [DOI: 10.1002/ejoc.201600705] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Dominique Schäfer
- Forschungszentrum Jülich GmbH; Institut für Neurowissenschaften und Medizin; INM-5: Nuklearchemie; 52425 Jülich Germany
| | - Philipp Weiß
- Forschungszentrum Jülich GmbH; Institut für Neurowissenschaften und Medizin; INM-5: Nuklearchemie; 52425 Jülich Germany
| | - Johannes Ermert
- Forschungszentrum Jülich GmbH; Institut für Neurowissenschaften und Medizin; INM-5: Nuklearchemie; 52425 Jülich Germany
| | - Johnny Castillo Meleán
- Forschungszentrum Jülich GmbH; Institut für Neurowissenschaften und Medizin; INM-5: Nuklearchemie; 52425 Jülich Germany
| | - Fadi Zarrad
- Forschungszentrum Jülich GmbH; Institut für Neurowissenschaften und Medizin; INM-5: Nuklearchemie; 52425 Jülich Germany
| | - Bernd Neumaier
- Forschungszentrum Jülich GmbH; Institut für Neurowissenschaften und Medizin; INM-5: Nuklearchemie; 52425 Jülich Germany
- Institute of Radiochemistry and Experimental Molecular Imaging; University Hospital Cologne; Kerpener Str. 62 50937 Cologne Germany
| |
Collapse
|
130
|
Rohleder C, Wiedermann D, Neumaier B, Drzezga A, Timmermann L, Graf R, Leweke FM, Endepols H. The Functional Networks of Prepulse Inhibition: Neuronal Connectivity Analysis Based on FDG-PET in Awake and Unrestrained Rats. Front Behav Neurosci 2016; 10:148. [PMID: 27493627 PMCID: PMC4954847 DOI: 10.3389/fnbeh.2016.00148] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Accepted: 07/06/2016] [Indexed: 12/21/2022] Open
Abstract
Prepulse inhibition (PPI) is a neuropsychological process during which a weak sensory stimulus (“prepulse”) attenuates the motor response (“startle reaction”) to a subsequent strong startling stimulus. It is measured as a surrogate marker of sensorimotor gating in patients suffering from neuropsychological diseases such as schizophrenia, as well as in corresponding animal models. A variety of studies has shown that PPI of the acoustical startle reaction comprises three brain circuitries for: (i) startle mediation, (ii) PPI mediation, and (iii) modulation of PPI mediation. While anatomical connections and information flow in the startle and PPI mediation pathways are well known, spatial and temporal interactions of the numerous regions involved in PPI modulation are incompletely understood. We therefore combined [18F]fluoro-2-deoxyglucose positron-emission-tomography (FDG-PET) with PPI and resting state control paradigms in awake rats. A battery of subtractive, correlative as well as seed-based functional connectivity analyses revealed a default mode-like network (DMN) active during resting state only. Furthermore, two functional networks were observed during PPI: Metabolic activity in the lateral circuitry was positively correlated with PPI effectiveness and involved the auditory system and emotional regions. The medial network was negatively correlated with PPI effectiveness, i.e., associated with startle, and recruited a spatial/cognitive network. Our study provides evidence for two distinct neuronal networks, whose continuous interplay determines PPI effectiveness in rats, probably by either protecting the prepulse or facilitating startle processing. Discovering similar networks affected in neuropsychological disorders may help to better understand mechanisms of sensorimotor gating deficits and provide new perspectives for therapeutic strategies.
Collapse
Affiliation(s)
- Cathrin Rohleder
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg UniversityMannheim, Germany; Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of CologneCologne, Germany
| | - Dirk Wiedermann
- In-Vivo NMR Laboratory, Max-Planck-Institute for Metabolism Research Cologne, Germany
| | - Bernd Neumaier
- Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of CologneCologne, Germany; Forschungszentrum Jülich GmbH, Institute of Neurosciences and Medicine, INM-5: Nuclear ChemistryJülich, Germany
| | - Alexander Drzezga
- Department of Nuclear Medicine, University Hospital of Cologne Cologne, Germany
| | - Lars Timmermann
- Department of Neurology, University Hospital of Cologne Cologne, Germany
| | - Rudolf Graf
- Multimodal Imaging of Brain Metabolism, Max-Planck-Institute for Metabolism Research Cologne, Germany
| | - F Markus Leweke
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University Mannheim, Germany
| | - Heike Endepols
- Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne Cologne, Germany
| |
Collapse
|
131
|
Klein R, Mahlberg N, Ohren M, Ladwig A, Neumaier B, Graf R, Hoehn M, Albrechtsen M, Rees S, Fink GR, Rueger MA, Schroeter M. The Neural Cell Adhesion Molecule-Derived (NCAM)-Peptide FG Loop (FGL) Mobilizes Endogenous Neural Stem Cells and Promotes Endogenous Regenerative Capacity after Stroke. J Neuroimmune Pharmacol 2016; 11:708-720. [DOI: 10.1007/s11481-016-9694-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Accepted: 06/20/2016] [Indexed: 12/20/2022]
|
132
|
Abstract
Abstract
Alpha particles exhibit three important characteristics: scattering, ionisation and activation. This article briefly discusses those properties and outlines their major applications. Among others, α-particles are used in elemental analysis, investigation and improvement of materials properties, nuclear reaction studies and medical radionuclide production. The latter two topics, dealing with activation of target materials, are treated in some detail in this paper. Measurements of excitation functions of α-particle induced reactions shed some light on their reaction mechanisms, and studies of isomeric cross sections reveal the probability of population of high-spin nuclear levels. Regarding medical radionuclides, an overview is presented of the isotopes commonly produced using α-particle beams. Consideration is also given to some routes which could be potentially useful for production of a few other radionuclides. The significance of α-particle induced reactions to produce a few high-spin isomeric states, decaying by emission of low-energy conversion or Auger electrons, which are of interest in localized internal radiotherapy, is outlined. The α-particle beam, thus broadens the scope of nuclear chemistry research related to development of non-standard positron emitters and therapeutic radionuclides.
Collapse
Affiliation(s)
- Syed M. Qaim
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich, D-52425 Jülich, Germany
| | - Ingo Spahn
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich, D-52425 Jülich, Germany
| | - Bernhard Scholten
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich, D-52425 Jülich, Germany
| | - Bernd Neumaier
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich, D-52425 Jülich, Germany
| |
Collapse
|
133
|
Affiliation(s)
- Christian Vanasschen
- Institute of Neuroscience and Medicine, INM-5 - Nuclear Chemistry, Forschungszentrum Jülich, Germany
| | - Marie Brandt
- Institute of Neuroscience and Medicine, INM-5 - Nuclear Chemistry, Forschungszentrum Jülich, Germany
| | - Johannes Ermert
- Institute of Neuroscience and Medicine, INM-5 - Nuclear Chemistry, Forschungszentrum Jülich, Germany
| | - Bernd Neumaier
- Institute for Radiochemistry and Experimental Molecular Imaging, Medical Clinics, University of Cologne, Germany
| | - Heinz H Coenen
- Institute of Neuroscience and Medicine, INM-5 - Nuclear Chemistry, Forschungszentrum Jülich, Germany
| |
Collapse
|
134
|
Braun R, Klein R, Walter HL, Ohren M, Freudenmacher L, Getachew K, Ladwig A, Luelling J, Neumaier B, Endepols H, Graf R, Hoehn M, Fink GR, Schroeter M, Rueger MA. Transcranial direct current stimulation accelerates recovery of function, induces neurogenesis and recruits oligodendrocyte precursors in a rat model of stroke. Exp Neurol 2016; 279:127-136. [PMID: 26923911 DOI: 10.1016/j.expneurol.2016.02.018] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2015] [Revised: 02/22/2016] [Accepted: 02/24/2016] [Indexed: 12/17/2022]
Abstract
BACKGROUND Clinical data suggest that transcranial direct current stimulation (tDCS) may be used to facilitate rehabilitation after stroke. However, data are inconsistent and the neurobiological mechanisms underlying tDCS remain poorly explored, impeding its implementation into clinical routine. In the healthy rat brain, tDCS affects neural stem cells (NSC) and microglia. We here investigated whether tDCS applied after stroke also beneficially affects these cells, which are known to be involved in regeneration and repair. METHODS Focal cerebral ischemia was induced in rats by transient occlusion of the middle cerebral artery. Twenty-eight animals with comparable infarcts, as judged by magnetic resonance imaging, were randomized to receive a multi-session paradigm of either cathodal, anodal, or sham tDCS. Behaviorally, recovery of motor function was assessed by Catwalk. Proliferation in the NSC niches was monitored by Positron-Emission-Tomography (PET) employing the radiotracer 3'-deoxy-3'-[(18)F]fluoro-l-thymidine ([(18)F]FLT). Microglia activation was depicted with [(11)C]PK11195-PET. In addition, immunohistochemical analyses were used to quantify neuroblasts, oligodendrocyte precursors, and activation and polarization of microglia. RESULTS Anodal and cathodal tDCS both accelerated functional recovery, though affecting different aspects of motor function. Likewise, tDCS induced neurogenesis independently of polarity, while only cathodal tDCS recruited oligodendrocyte precursors towards the lesion. Moreover, cathodal stimulation preferably supported M1-polarization of microglia. CONCLUSIONS TDCS acts through multifaceted mechanisms that far exceed its primary neurophysiological effects, encompassing proliferation and migration of stem cells, their neuronal differentiation, and modulation of microglia responses.
Collapse
Affiliation(s)
- Ramona Braun
- Department of Neurology, University Hospital of Cologne, Kerpener Str. 62, 50924 Cologne, Germany; Max Planck Institute for Metabolism Research, Gleueler Str. 50, 50931 Cologne, Germany
| | - Rebecca Klein
- Department of Neurology, University Hospital of Cologne, Kerpener Str. 62, 50924 Cologne, Germany
| | - Helene Luise Walter
- Department of Neurology, University Hospital of Cologne, Kerpener Str. 62, 50924 Cologne, Germany
| | - Maurice Ohren
- Department of Neurology, University Hospital of Cologne, Kerpener Str. 62, 50924 Cologne, Germany
| | - Lars Freudenmacher
- Department of Neurology, University Hospital of Cologne, Kerpener Str. 62, 50924 Cologne, Germany
| | - Kaleab Getachew
- Department of Neurology, University Hospital of Cologne, Kerpener Str. 62, 50924 Cologne, Germany
| | - Anne Ladwig
- Department of Neurology, University Hospital of Cologne, Kerpener Str. 62, 50924 Cologne, Germany; Max Planck Institute for Metabolism Research, Gleueler Str. 50, 50931 Cologne, Germany
| | - Joachim Luelling
- Department of Neurology, University Hospital of Cologne, Kerpener Str. 62, 50924 Cologne, Germany
| | - Bernd Neumaier
- Department of Nuclear Medicine, University Hospital of Cologne, Kerpener Str. 62, 50924 Cologne, Germany; Max Planck Institute for Metabolism Research, Gleueler Str. 50, 50931 Cologne, Germany
| | - Heike Endepols
- Department of Nuclear Medicine, University Hospital of Cologne, Kerpener Str. 62, 50924 Cologne, Germany
| | - Rudolf Graf
- Max Planck Institute for Metabolism Research, Gleueler Str. 50, 50931 Cologne, Germany
| | - Mathias Hoehn
- Max Planck Institute for Metabolism Research, Gleueler Str. 50, 50931 Cologne, Germany
| | - Gereon Rudolf Fink
- Department of Neurology, University Hospital of Cologne, Kerpener Str. 62, 50924 Cologne, Germany; Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Centre Juelich, 52425 Juelich, Germany
| | - Michael Schroeter
- Department of Neurology, University Hospital of Cologne, Kerpener Str. 62, 50924 Cologne, Germany; Max Planck Institute for Metabolism Research, Gleueler Str. 50, 50931 Cologne, Germany; Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Centre Juelich, 52425 Juelich, Germany
| | - Maria Adele Rueger
- Department of Neurology, University Hospital of Cologne, Kerpener Str. 62, 50924 Cologne, Germany; Max Planck Institute for Metabolism Research, Gleueler Str. 50, 50931 Cologne, Germany; Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Centre Juelich, 52425 Juelich, Germany.
| |
Collapse
|
135
|
Backes H, Walberer M, Ladwig A, Rueger MA, Neumaier B, Endepols H, Hoehn M, Fink GR, Schroeter M, Graf R. Glucose consumption of inflammatory cells masks metabolic deficits in the brain. Neuroimage 2015; 128:54-62. [PMID: 26747749 PMCID: PMC4767221 DOI: 10.1016/j.neuroimage.2015.12.044] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Revised: 12/16/2015] [Accepted: 12/23/2015] [Indexed: 01/06/2023] Open
Abstract
Inflammatory cells such as microglia need energy to exert their functions and to maintain their cellular integrity and membrane potential. Subsequent to cerebral ischemia, inflammatory cells infiltrate tissue with limited blood flow where neurons and astrocytes died due to insufficient supply with oxygen and glucose. Using dual tracer positron emission tomography (PET), we found that concomitant with the presence of inflammatory cells, transport and consumption of glucose increased up to normal levels but returned to pathological levels as soon as inflammatory cells disappeared. Thus, inflammatory cells established sufficient glucose supply to satisfy their energy demands even in regions with insufficient supply for neurons and astrocytes to survive. Our data suggest that neurons and astrocytes died from oxygen deficiency and inflammatory cells metabolized glucose non-oxidatively in regions with residual availability. As a consequence, glucose metabolism of inflammatory cells can mask metabolic deficits in neurodegenerative diseases. We further found that the PET tracer did not bind to inflammatory cells in severely hypoperfused regions and thus only a part of the inflammation was detected. We conclude that glucose consumption of inflammatory cells should be taken into account when analyzing disease-related alterations of local cerebral metabolism. Inflammatory cells consume high amounts of glucose in supply-limited brain regions. Glucose metabolism of inflammatory cells masks metabolic deficits in the brain. In vivo markers only reach inflammatory cells in regions with residual blood supply. Measuring inflammation and metabolism provide complementary information.
Collapse
Affiliation(s)
- Heiko Backes
- Max Planck Institute for Metabolism Research, Cologne, Germany.
| | - Maureen Walberer
- Max Planck Institute for Metabolism Research, Cologne, Germany; Department of Neurology, University Hospital, Cologne, Germany
| | - Anne Ladwig
- Max Planck Institute for Metabolism Research, Cologne, Germany; Department of Neurology, University Hospital, Cologne, Germany
| | - Maria A Rueger
- Max Planck Institute for Metabolism Research, Cologne, Germany; Department of Neurology, University Hospital, Cologne, Germany
| | - Bernd Neumaier
- Max Planck Institute for Metabolism Research, Cologne, Germany; Department of Radiochemistry and Experimental Molecular Imaging, University of Cologne, Germany
| | - Heike Endepols
- Department of Radiochemistry and Experimental Molecular Imaging, University of Cologne, Germany
| | - Mathias Hoehn
- Max Planck Institute for Metabolism Research, Cologne, Germany
| | - Gereon R Fink
- Department of Neurology, University Hospital, Cologne, Germany; Institute of Neuroscience and Medicine (INM-3), Cognitive Neurology Section, Research Centre Juelich, Germany
| | - Michael Schroeter
- Max Planck Institute for Metabolism Research, Cologne, Germany; Department of Neurology, University Hospital, Cologne, Germany
| | - Rudolf Graf
- Max Planck Institute for Metabolism Research, Cologne, Germany
| |
Collapse
|
136
|
Krapf P, Richarz R, Urusova EA, Neumaier B, Zlatopolskiy BD. Seyferth-Gilbert Homologation as a Route to18F-Labeled Building Blocks: Preparation of Radiofluorinated Phenylacetylenes and Their Application in PET Chemistry. European J Org Chem 2015. [DOI: 10.1002/ejoc.201501377] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
137
|
Kobe C, Boellaard R, Wolf J, Kuhnert G, Dietlein M, Neumaier B, Drzezga A, Kahraman D. Developments in oncological positron emission tomography/computed tomography assessment. J Thorac Dis 2015; 7:E637-9. [PMID: 26793379 PMCID: PMC4703688 DOI: 10.3978/j.issn.2072-1439.2015.12.45] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
138
|
Affiliation(s)
- Heinrich H Coenen
- Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Research Centre, Jülich, Germany
| | - Martin Buchholz
- Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Research Centre, Jülich, Germany
| | - Ingo Spahn
- Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Research Centre, Jülich, Germany
| | - Christian Vanasschen
- Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Research Centre, Jülich, Germany
| | - Johannes Ermert
- Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Research Centre, Jülich, Germany
| | - Bernd Neumaier
- Institute for Radiochemistry and Experimental Molecular Imaging, Medical Clinics, University of Cologne, Kragujevac, Germany
| |
Collapse
|
139
|
Zlatopolskiy BD, Zischler J, Urusova EA, Endepols H, Kordys E, Frauendorf H, Mottaghy FM, Neumaier B. A Practical One-Pot Synthesis of Positron Emission Tomography (PET) Tracers via Nickel-Mediated Radiofluorination. ChemistryOpen 2015; 4:395. [PMID: 26478831 PMCID: PMC4603396 DOI: 10.1002/open.201500144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Invited for this months cover picture is the group of Professor Bernd Neumaier at the Institute of Radiochemistry and Experimental Molecular Imaging at the University Clinic of Cologne. The cover picture shows the differences in brain metabolism of a healthy young and a healthy old subject, as well as a patient suffering from Parkinsons disease (left to right) uncovered by 6-[18F]FDOPA-positron emission tomography (PET). Morbus Parkinson occurs when nerve cells that produce dopamine begin to die. The shortage of dopamine leads to movement problems in affected individuals. 6-[18F]FDOPA is extensively used to evaluate the progression of Parkinsons disease. Bold stick projections of this PET tracer, as well as a neuronal network, are seen in the background. Unfortunately, conventional procedures to produce 6-[18F]FDOPA are cumbersome. Thus, several recent developments aim at the simplification of this radiosynthesis. In our work, we studied the applicability of the recently reported Ni-mediated radiofluorination approach for daily routine production of 6-[18F]FDOPA. For more details, see the Full Paper on p. 457 ff.
Collapse
Affiliation(s)
- Boris D Zlatopolskiy
- Institute of Radiochemistry & Experimental Molecular Imaging, University Clinic Cologne Kerpener Str. 62, 50937, Cologne, Germany ; Max Planck Institute for Metabolism Research Gleueler Str. 50, 50931, Cologne, Germany
| | - Johannes Zischler
- Institute of Radiochemistry & Experimental Molecular Imaging, University Clinic Cologne Kerpener Str. 62, 50937, Cologne, Germany ; Max Planck Institute for Metabolism Research Gleueler Str. 50, 50931, Cologne, Germany
| | - Elizaveta A Urusova
- Institute of Radiochemistry & Experimental Molecular Imaging, University Clinic Cologne Kerpener Str. 62, 50937, Cologne, Germany ; Max Planck Institute for Metabolism Research Gleueler Str. 50, 50931, Cologne, Germany ; Clinic of Nuclear Medicine, RWTH Aachen University Pauwelsstraße 30, 52074, Aachen, Germany
| | - Heike Endepols
- Institute of Radiochemistry & Experimental Molecular Imaging, University Clinic Cologne Kerpener Str. 62, 50937, Cologne, Germany ; Max Planck Institute for Metabolism Research Gleueler Str. 50, 50931, Cologne, Germany
| | - Elena Kordys
- Institute of Radiochemistry & Experimental Molecular Imaging, University Clinic Cologne Kerpener Str. 62, 50937, Cologne, Germany ; Max Planck Institute for Metabolism Research Gleueler Str. 50, 50931, Cologne, Germany
| | - Holm Frauendorf
- Institute of Organic & Biomolecular Chemistry, Georg-August University Tammannstr. 2, 37077, Göttingen, Germany
| | - Felix M Mottaghy
- Clinic of Nuclear Medicine, RWTH Aachen University Pauwelsstraße 30, 52074, Aachen, Germany ; Department of Nuclear Medicine, Maastricht University Medical Center PO Box 616, 6200, MD Maastricht, The Netherlands
| | - Bernd Neumaier
- Institute of Radiochemistry & Experimental Molecular Imaging, University Clinic Cologne Kerpener Str. 62, 50937, Cologne, Germany ; Max Planck Institute for Metabolism Research Gleueler Str. 50, 50931, Cologne, Germany
| |
Collapse
|
140
|
Endepols H, Mertgens H, Backes H, Himmelreich U, Neumaier B, Graf R, Mies G. Longitudinal assessment of infarct progression, brain metabolism and behavior following anterior cerebral artery occlusion in rats. J Neurosci Methods 2015; 253:279-91. [DOI: 10.1016/j.jneumeth.2014.11.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2014] [Revised: 10/16/2014] [Accepted: 11/04/2014] [Indexed: 10/24/2022]
|
141
|
Zlatopolskiy BD, Zischler J, Urusova EA, Endepols H, Kordys E, Frauendorf H, Mottaghy FM, Neumaier B. Cover Picture: A Practical One-Pot Synthesis of Positron Emission Tomography (PET) Tracers via Nickel-Mediated Radiofluorination (ChemistryOpen 4/2015). Chemistry 2015. [PMCID: PMC4603395 DOI: 10.1002/open.201580401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Boris D. Zlatopolskiy
- Institute of Radiochemistry & Experimental Molecular Imaging; University Clinic Cologne; Kerpener Str. 62 50937 Cologne Germany
- Max Planck Institute for Metabolism Research; Gleueler Str. 50 50931 Cologne Germany
| | - Johannes Zischler
- Institute of Radiochemistry & Experimental Molecular Imaging; University Clinic Cologne; Kerpener Str. 62 50937 Cologne Germany
- Max Planck Institute for Metabolism Research; Gleueler Str. 50 50931 Cologne Germany
| | - Elizaveta A. Urusova
- Institute of Radiochemistry & Experimental Molecular Imaging; University Clinic Cologne; Kerpener Str. 62 50937 Cologne Germany
- Max Planck Institute for Metabolism Research; Gleueler Str. 50 50931 Cologne Germany
- Clinic of Nuclear Medicine; RWTH Aachen University; Pauwelsstraße 30 52074 Aachen Germany
| | - Heike Endepols
- Institute of Radiochemistry & Experimental Molecular Imaging; University Clinic Cologne; Kerpener Str. 62 50937 Cologne Germany
- Max Planck Institute for Metabolism Research; Gleueler Str. 50 50931 Cologne Germany
| | - Elena Kordys
- Institute of Radiochemistry & Experimental Molecular Imaging; University Clinic Cologne; Kerpener Str. 62 50937 Cologne Germany
- Max Planck Institute for Metabolism Research; Gleueler Str. 50 50931 Cologne Germany
| | - Holm Frauendorf
- Institute of Organic & Biomolecular Chemistry; Georg-August University; Tammannstr. 2 37077 Göttingen Germany
| | - Felix M. Mottaghy
- Clinic of Nuclear Medicine; RWTH Aachen University; Pauwelsstraße 30 52074 Aachen Germany
- Department of Nuclear Medicine; Maastricht University Medical Center; PO Box 616 6200 MD Maastricht The Netherlands
| | - Bernd Neumaier
- Institute of Radiochemistry & Experimental Molecular Imaging; University Clinic Cologne; Kerpener Str. 62 50937 Cologne Germany
- Max Planck Institute for Metabolism Research; Gleueler Str. 50 50931 Cologne Germany
| |
Collapse
|
142
|
Zlatopolskiy BD, Zischler J, Urusova EA, Endepols H, Kordys E, Frauendorf H, Mottaghy FM, Neumaier B. A Practical One-Pot Synthesis of Positron Emission Tomography (PET) Tracers via Nickel-Mediated Radiofluorination. ChemistryOpen 2015; 4:457-62. [PMID: 26478840 PMCID: PMC4603406 DOI: 10.1002/open.201500056] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2015] [Indexed: 12/28/2022] Open
Abstract
Recently a novel method for the preparation of (18)F-labeled arenes via oxidative [(18)F]fluorination of easily accessible and sufficiently stable nickel complexes with [(18)F]fluoride under exceptionally mild reaction conditions was published. The suitability of this procedure for the routine preparation of clinically relevant positron emission tomography (PET) tracers, 6-[(18)F]fluorodopamine (6-[(18)F]FDA), 6-[(18)F]fluoro-l-DOPA (6-[(18)F]FDOPA) and 6-[(18)F]fluoro-m-tyrosine (6-[(18)F]FMT), was evaluated. The originally published base-free method was inoperative. However, a "low base" protocol afforded protected radiolabeled intermediates in radiochemical conversions (RCCs) of 5-18 %. The subsequent deprotection step proceeded almost quantitatively (>95 %). The simple one-pot two-step procedure allowed the preparation of clinical doses of 6-[(18)F]FDA and 6-[(18)F]FDOPA within 50 min (12 and 7 % radiochemical yield, respectively). In an unilateral rat model of Parkinsons disease, 6-[(18)F]FDOPA with high specific activity (175 GBq μmol(-1)) prepared using the described nickel-mediated radiofluorination was compared to 6-[(18)F]FDOPA with low specific activity (30 MBq μmol(-1)) produced via conventional electrophilic radiofluorination. Unexpectedly both tracer variants displayed very similar in vivo properties with respect to signal-to-noise ratio and brain distribution, and consequently, the quality of the obtained PET images was almost identical.
Collapse
Affiliation(s)
- Boris D Zlatopolskiy
- Institute of Radiochemistry & Experimental Molecular Imaging, University Clinic CologneKerpener Str. 62, 50937, Cologne, Germany
- Max Planck Institute for Metabolism ResearchGleueler Str. 50, 50931, Cologne, Germany
| | - Johannes Zischler
- Institute of Radiochemistry & Experimental Molecular Imaging, University Clinic CologneKerpener Str. 62, 50937, Cologne, Germany
- Max Planck Institute for Metabolism ResearchGleueler Str. 50, 50931, Cologne, Germany
| | - Elizaveta A Urusova
- Institute of Radiochemistry & Experimental Molecular Imaging, University Clinic CologneKerpener Str. 62, 50937, Cologne, Germany
- Max Planck Institute for Metabolism ResearchGleueler Str. 50, 50931, Cologne, Germany
- Clinic of Nuclear Medicine, RWTH Aachen UniversityPauwelsstraße 30, 52074, Aachen, Germany
| | - Heike Endepols
- Institute of Radiochemistry & Experimental Molecular Imaging, University Clinic CologneKerpener Str. 62, 50937, Cologne, Germany
- Max Planck Institute for Metabolism ResearchGleueler Str. 50, 50931, Cologne, Germany
| | - Elena Kordys
- Institute of Radiochemistry & Experimental Molecular Imaging, University Clinic CologneKerpener Str. 62, 50937, Cologne, Germany
- Max Planck Institute for Metabolism ResearchGleueler Str. 50, 50931, Cologne, Germany
| | - Holm Frauendorf
- Institute of Organic & Biomolecular Chemistry, Georg-August UniversityTammannstr. 2, 37077, Göttingen, Germany
| | - Felix M Mottaghy
- Clinic of Nuclear Medicine, RWTH Aachen UniversityPauwelsstraße 30, 52074, Aachen, Germany
- Department of Nuclear Medicine, Maastricht University Medical CenterPO Box 616, 6200, MD Maastricht, The Netherlands
| | - Bernd Neumaier
- Institute of Radiochemistry & Experimental Molecular Imaging, University Clinic CologneKerpener Str. 62, 50937, Cologne, Germany
- Max Planck Institute for Metabolism ResearchGleueler Str. 50, 50931, Cologne, Germany
| |
Collapse
|
143
|
Klein R, Blaschke S, Neumaier B, Endepols H, Graf R, Keuters M, Hucklenbroich J, Albrechtsen M, Rees S, Fink GR, Schroeter M, Rueger MA. The synthetic NCAM mimetic peptide FGL mobilizes neural stem cells in vitro and in vivo. Stem Cell Rev Rep 2015; 10:539-47. [PMID: 24817672 DOI: 10.1007/s12015-014-9512-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
The neural cell adhesion molecule (NCAM) plays a role in neurite outgrowth, synaptogenesis, and neuronal differentiation. The NCAM mimetic peptide FG Loop (FGL) promotes neuronal survival in vitro and enhances spatial learning and memory in rats. We here investigated the effects of FGL on neural stem cells (NSC) in vitro and in vivo. In vitro, cell proliferation of primary NSC was assessed after exposure to various concentrations of NCAM or FGL. The differentiation potential of NCAM- or FGL-treated cells was assessed immunocytochemically. To investigate its influence on endogenous NSC in vivo, FGL was injected subcutaneously into adult rats. The effects on NSC mobilization were studied both via non-invasive positron emission tomography (PET) imaging using the tracer [(18)F]-fluoro-L-thymidine ([(18)F]FLT), as well as with immunohistochemistry. Only FGL significantly enhanced NSC proliferation in vitro, with a maximal effect at 10 μg/ml. During differentiation, NCAM promoted neurogenesis, while FGL induced an oligodendroglial phenotype; astrocytic differentiation was neither affected by NCAM or FGL. Those differential effects of NCAM and FGL on differentiation were mediated through different receptors. After FGL-injection in vivo, proliferative activity of NSC in the subventricular zone (SVZ) was increased (compared to placebo-treated animals). Moreover, non-invasive imaging of cell proliferation using [(18)F]FLT-PET supported an FGL-induced mobilization of NSC from both the SVZ and the hippocampus. We conclude that FGL robustly induces NSC mobilization in vitro and in vivo, and supports oligodendroglial differentiation. This capacity renders FGL a promising agent to facilitate remyelinization, which may eventually make FGL a drug candidate for demyelinating neurological disorders.
Collapse
Affiliation(s)
- Rebecca Klein
- Department of Neurology, University Hospital of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
144
|
Frese J, Morgenroth A, Mertens ME, Koch S, Rongen L, Vogg ATJ, Zlatopolskiy BD, Neumaier B, Gesche VN, Lammers T, Schmitz-Rode T, Mela P, Jockenhoevel S, Mottaghy FM, Kiessling F. Nondestructive monitoring of tissue-engineered constructs. ACTA ACUST UNITED AC 2015; 59:165-75. [PMID: 24021591 DOI: 10.1515/bmt-2013-0029] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2013] [Accepted: 08/13/2013] [Indexed: 11/15/2022]
Abstract
Abstract Tissue engineering as a multidisciplinary field enables the development of living substitutes to replace, maintain, or restore diseased tissue and organs. Since the term was introduced in medicine in 1987, tissue engineering strategies have experienced significant progress. However, up to now, only a few substitutes were able to overcome the gap from bench to bedside and have been successfully approved for clinical use. Substantial donor variability makes it difficult to predict the quality of tissue-engineered constructs. It is essential to collect sufficient data to ensure that poor or immature constructs are not implanted into patients. The fulfillment of certain quality requirements, such as mechanical and structural properties, is crucial for a successful implantation. There is a clear need for new nondestructive and real-time online monitoring and evaluation methods for tissue-engineered constructs, which are applicable on the biomaterial, tissue, cellular, and subcellular levels. This paper reviews current established nondestructive techniques for implant monitoring including biochemical methods and noninvasive imaging.
Collapse
|
145
|
Zlatopolskiy BD, Zischler J, Krapf P, Zarrad F, Urusova EA, Kordys E, Endepols H, Neumaier B. Copper-mediated aromatic radiofluorination revisited: efficient production of PET tracers on a preparative scale. Chemistry 2015; 21:5972-9. [PMID: 25708748 DOI: 10.1002/chem.201405586] [Citation(s) in RCA: 101] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Indexed: 11/08/2022]
Abstract
Two novel methods for copper-mediated aromatic nucleophilic radiofluorination were recently reported. Evaluation of these methods reveals that, although both are efficient in small-scale experiments, they are inoperative for the production of positron emission tomography (PET) tracers. Since high base content turned out to be responsible for low radiochemical conversions, a "low base" protocol has been developed which affords (18)F-labeled arenes from diaryliodonium salts and aryl pinacol boronates in reasonable yields. Furthermore, implementation of our "minimalist" approach to the copper-mediated [(18)F]-fluorination of (mesityl)(aryl)iodonium salts allows the preparation of (18)F-labeled arenes in excellent RCCs. The novel radiofluorination method circumvents time-consuming azeotropic drying and avoids the utilization of base and other additives, such as cryptands. Furthermore, this procedure enables the production of clinically relevant PET tracers; [(18)F]FDA, 4-[(18)F]FPhe, and [(18)F]DAA1106 are obtained in good isolated radiochemical yields. Additionally, [(18)F]DAA1106 has been evaluated in a rat stroke model and demonstrates excellent potential for visualization of translocator protein 18 kDa overexpression associated with neuroinflammation after ischemic stroke.
Collapse
Affiliation(s)
- Boris D Zlatopolskiy
- Institute of Radiochemistry and Experimental Molecular Imaging, University Clinic Cologne, Kerpener Str. 62, 50937 Cologne (Germany), Fax: (+49) 221-47886851; Max Planck Institute for Metabolism Research, Gleueler Str. 50, 50931 Cologne (Germany)
| | | | | | | | | | | | | | | |
Collapse
|
146
|
Hucklenbroich J, Klein R, Neumaier B, Graf R, Fink GR, Schroeter M, Rueger MA. Aromatic-turmerone induces neural stem cell proliferation in vitro and in vivo. Stem Cell Res Ther 2014; 5:100. [PMID: 25928248 PMCID: PMC4180255 DOI: 10.1186/scrt500] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2014] [Revised: 08/12/2014] [Accepted: 08/12/2014] [Indexed: 12/19/2022] Open
Abstract
Introduction Aromatic (ar-) turmerone is a major bioactive compound of the herb Curcuma longa. It has been suggested that ar-turmerone inhibits microglia activation, a property that may be useful in treating neurodegenerative disease. Furthermore, the effects of ar-turmerone on neural stem cells (NSCs) remain to be investigated. Methods We exposed primary fetal rat NSCs to various concentrations of ar-turmerone. Thereafter, cell proliferation and differentiation potential were assessed. In vivo, naïve rats were treated with a single intracerebroventricular (i.c.v.) injection of ar-turmerone. Proliferative activity of endogenous NSCs was assessed in vivo, by using noninvasive positron emission tomography (PET) imaging and the tracer [18F]-fluoro-L-thymidine ([18F]FLT), as well as ex vivo. Results In vitro, ar-turmerone increased dose-dependently the number of cultured NSCs, because of an increase in NSC proliferation (P < 0.01). Proliferation data were supported by qPCR-data for Ki-67 mRNA. In vitro as well as in vivo, ar-turmerone promoted neuronal differentiation of NSCs. In vivo, after i.c.v. injection of ar-turmerone, proliferating NSCs were mobilized from the subventricular zone (SVZ) and the hippocampus of adult rats, as demonstrated by both [18F]FLT-PET and histology (P < 0.05). Conclusions Both in vitro and in vivo data suggest that ar-turmerone induces NSC proliferation. Ar-turmerone thus constitutes a promising candidate to support regeneration in neurologic disease.
Collapse
Affiliation(s)
- Joerg Hucklenbroich
- Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Centre Juelich, Leo-Brandt-Straße 52425, Jülich, Germany. .,Department of Neurology, University Hospital of Cologne, Cologne, Germany.
| | - Rebecca Klein
- Department of Neurology, University Hospital of Cologne, Cologne, Germany. .,Max Planck Institute for Neurological Research, Cologne, Germany.
| | - Bernd Neumaier
- Max Planck Institute for Neurological Research, Cologne, Germany.
| | - Rudolf Graf
- Max Planck Institute for Neurological Research, Cologne, Germany.
| | - Gereon Rudolf Fink
- Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Centre Juelich, Leo-Brandt-Straße 52425, Jülich, Germany. .,Department of Neurology, University Hospital of Cologne, Cologne, Germany.
| | - Michael Schroeter
- Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Centre Juelich, Leo-Brandt-Straße 52425, Jülich, Germany. .,Department of Neurology, University Hospital of Cologne, Cologne, Germany. .,Max Planck Institute for Neurological Research, Cologne, Germany.
| | - Maria Adele Rueger
- Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Centre Juelich, Leo-Brandt-Straße 52425, Jülich, Germany. .,Department of Neurology, University Hospital of Cologne, Cologne, Germany. .,Max Planck Institute for Neurological Research, Cologne, Germany.
| |
Collapse
|
147
|
Walberer M, Jantzen SU, Backes H, Rueger MA, Keuters MH, Neumaier B, Hoehn M, Fink GR, Graf R, Schroeter M. In-vivo detection of inflammation and neurodegeneration in the chronic phase after permanent embolic stroke in rats. Brain Res 2014; 1581:80-8. [PMID: 24905627 DOI: 10.1016/j.brainres.2014.05.030] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2014] [Revised: 05/07/2014] [Accepted: 05/21/2014] [Indexed: 11/25/2022]
Abstract
Neuroinflammation with microglia activation (MA) constitutes a key tissue response in acute stroke. Until now, its course in the chronic stage is less well defined. Here, we investigated (i) neuroinflammation in the chronic stage of a rat model of embolic stroke (n=6), and (ii) whether this process can be visualized in vivo by multimodal imaging using Magnetic Resonance Imaging (MRI) and Positron-Emission-Tomography (PET). Imaging data were verified using histology and immunohistochemistry. Repetitive PET studies until week 6 after stroke reveal poststroke inflammation as a dynamic process that involved the infarct, the surrounding tissue and secondary degenerating areas in a complex fashion. At the end, 7 months after stroke, neuroinflammation had almost completely vanished at the lesion side. In contrast, remote from the primarily infarcted areas, a marked T2(*)- hypointensity was detected in the ipsilateral thalamus. In the corresponding area, [(11)C]PK11195-PET detected microglia activation. Immunohistochemistry confirmed activated microglia in the ipsilateral thalamus with signs of extensive phagocytosis and iron deposition around plaque-like amyloid deposition. Neuronal staining (NeuN) revealed pronounced neuronal loss as an endpoint of neurodegeneration in these areas. In conclusion, the data demonstrate not only ongoing thalamic neuroinflammation but also marked neurodegeneration remote from the lesion site in the chronic phase after stroke in rats. Both, neuroinflammation and neurodegeneration were accessible to (immuno-) histochemical methods as well as to in vivo methods using [(11)C]PK11195-PET and T2(*)-weighted MRI. Although the functional roles of these dynamic processes remain to be elucidated, ongoing destruction of neuronal tissue is conceivable. Its inhibition using anti-inflammatory substances may be beneficial in chronic post-stroke conditions, while multimodal imaging can be used to evaluate putative therapeutic effects in vivo.
Collapse
Affiliation(s)
- Maureen Walberer
- Department of Neurology, University Hospital, Kerpener Str. 62, 50924 Cologne, Germany; Max Planck Institute for Neurological Research, Gleueler Str. 50, 50931 Cologne, Germany
| | - Sabine U Jantzen
- Department of Neurology, University Hospital, Kerpener Str. 62, 50924 Cologne, Germany; Max Planck Institute for Neurological Research, Gleueler Str. 50, 50931 Cologne, Germany
| | - Heiko Backes
- Max Planck Institute for Neurological Research, Gleueler Str. 50, 50931 Cologne, Germany
| | - Maria A Rueger
- Department of Neurology, University Hospital, Kerpener Str. 62, 50924 Cologne, Germany; Max Planck Institute for Neurological Research, Gleueler Str. 50, 50931 Cologne, Germany
| | - Meike H Keuters
- Department of Neurology, University Hospital, Kerpener Str. 62, 50924 Cologne, Germany; Max Planck Institute for Neurological Research, Gleueler Str. 50, 50931 Cologne, Germany
| | - Bernd Neumaier
- Max Planck Institute for Neurological Research, Gleueler Str. 50, 50931 Cologne, Germany
| | - Mathias Hoehn
- Max Planck Institute for Neurological Research, Gleueler Str. 50, 50931 Cologne, Germany
| | - Gereon R Fink
- Department of Neurology, University Hospital, Kerpener Str. 62, 50924 Cologne, Germany; Institute of Neuroscience and Medicine (INM-3), Cognitive Neuroscience, Research Centre Juelich, 52425 Juelich, Germany
| | - Rudolf Graf
- Max Planck Institute for Neurological Research, Gleueler Str. 50, 50931 Cologne, Germany
| | - Michael Schroeter
- Department of Neurology, University Hospital, Kerpener Str. 62, 50924 Cologne, Germany; Max Planck Institute for Neurological Research, Gleueler Str. 50, 50931 Cologne, Germany.
| |
Collapse
|
148
|
Rohleder C, Jung F, Mertgens H, Wiedermann D, Sué M, Neumaier B, Graf R, Leweke FM, Endepols H. Neural correlates of sensorimotor gating: a metabolic positron emission tomography study in awake rats. Front Behav Neurosci 2014; 8:178. [PMID: 24904330 PMCID: PMC4033256 DOI: 10.3389/fnbeh.2014.00178] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2014] [Accepted: 04/28/2014] [Indexed: 01/20/2023] Open
Abstract
Impaired sensorimotor gating occurs in neuropsychiatric disorders such as schizophrenia and can be measured using the prepulse inhibition (PPI) paradigm of the acoustic startle response. This assay is frequently used to validate animal models of neuropsychiatric disorders and to explore the therapeutic potential of new drugs. The underlying neural network of PPI has been extensively studied with invasive methods and genetic modifications. However, its relevance for healthy untreated animals and the functional interplay between startle- and PPI-related areas during a PPI session is so far unknown. Therefore, we studied awake rats in a PPI paradigm, startle control and background noise control, combined with behavioral [(18)F]fluoro-2-deoxyglucose positron emission tomography (FDG-PET). Subtractive analyses between conditions were used to identify brain regions involved in startle and PPI processing in well-hearing Black hooded rats. For correlative analysis with regard to the amount of PPI we also included hearing-impaired Lister hooded rats that startled more often, because their hearing threshold was just below the lowest prepulses. Metabolic imaging showed that the brain areas proposed for startle and PPI mediation are active during PPI paradigms in healthy untreated rats. More importantly, we show for the first time that the whole PPI modulation network is active during "passive" PPI sessions, where no selective attention to prepulse or startle stimulus is required. We conclude that this reflects ongoing monitoring of stimulus significance and constant adjustment of sensorimotor gating.
Collapse
Affiliation(s)
- Cathrin Rohleder
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg UniversityMannheim, Germany
- Multimodal Imaging, Max Planck Institute for Neurological ResearchCologne, Germany
| | - Fabienne Jung
- Multimodal Imaging, Max Planck Institute for Neurological ResearchCologne, Germany
| | - Hanna Mertgens
- Multimodal Imaging, Max Planck Institute for Neurological ResearchCologne, Germany
| | - Dirk Wiedermann
- Multimodal Imaging, Max Planck Institute for Neurological ResearchCologne, Germany
| | - Michael Sué
- Multimodal Imaging, Max Planck Institute for Neurological ResearchCologne, Germany
| | - Bernd Neumaier
- Multimodal Imaging, Max Planck Institute for Neurological ResearchCologne, Germany
| | - Rudolf Graf
- Multimodal Imaging, Max Planck Institute for Neurological ResearchCologne, Germany
| | - F. Markus Leweke
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg UniversityMannheim, Germany
| | - Heike Endepols
- Multimodal Imaging, Max Planck Institute for Neurological ResearchCologne, Germany
| |
Collapse
|
149
|
Scheffler M, Bos MCA, Sos ML, Heukamp LC, Nogova L, Koenig K, Gardizi M, Mattonet C, Kahraman D, Kobe C, Boellaard R, Lammertsma AA, Persigehl T, Engel-Riedel W, Toepelt K, Neumaier B, Büttner R, Zander T, Wolf J. MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET, DCE-MRI and molecular biomarkers for early prediction of nonprogression in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.e19049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Matthias Scheffler
- Lung Cancer Group Cologne, Department I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Marc Christiaan Allardt Bos
- Lung Cancer Group Cologne, Department I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Martin L. Sos
- UCSF School of Medicine, Cellular and Molecular Pharmacology, San Francisco, CA
| | - Lukas Carl Heukamp
- Institute of Pathology, University Hospital Cologne and Center for Integrated Oncology Köln-Bonn, Cologne, Germany
| | - Lucia Nogova
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Katharina Koenig
- Institute of Pathology, University Hospital Cologne and Center for Integrated Oncology Köln-Bonn, Cologne, Germany
| | - Masyar Gardizi
- Department I of Internal Medicine and Center for Integrated Oncology Köln-Bonn, University of Cologne, Cologne, Germany
| | - Christian Mattonet
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | | | | | - Ronald Boellaard
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands
| | | | | | | | - Karin Toepelt
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Koeln, Germany
| | - Bernd Neumaier
- Max Planck Institute for Neurological Research, Cologne, Germany
| | - Reinhard Büttner
- University Hospital Cologne, Institute of Pathology, Cologne, Germany
| | - Thomas Zander
- Department I for Internal Center, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| | - Juergen Wolf
- Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany
| |
Collapse
|
150
|
Chatterjee S, Wieczorek C, Schöttle J, Siobal M, Hinze Y, Franz T, Florin A, Adamczak J, Heukamp LC, Neumaier B, Ullrich RT. Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer. Cancer Res 2014; 74:2816-24. [PMID: 24675359 DOI: 10.1158/0008-5472.can-13-2986] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Extensive oncologic experience argues that the most efficacious applications of antiangiogenic agents rely upon a combination with cytotoxic drugs. Yet there remains a lack of clarity about how to optimize scheduling for such drug combinations. Prudent antiangiogenic therapy might transiently normalize blood vessels to improve tumor oxygenation and drug exposure. Using [(15)O]H2O positron emission tomography imaging in a preclinical mouse model of non-small cell lung cancer, we observed that short-term treatment with the vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibitor PTK787 licensed a transient window of improved tumor blood flow. The improvement observed was associated with a reduced leakiness from tumor vessels, consistent with induction of a vascular normalization process. Initiation of a cytotoxic treatment in this window of tumor vessel normalization resulted in increased efficacy, as illustrated by improved outcomes of erlotinib administration after initial PTK787 treatment. Notably, intermittent PTK787 treatment also facilitated long-term tumor regression. In summary, our findings offer strong evidence that short-term antiangiogenic therapy can promote a transient vessel normalization process that improves the delivery and efficacy of a targeted cytotoxic drug.
Collapse
Affiliation(s)
- Sampurna Chatterjee
- Authors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, GermanyAuthors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, GermanyAuthors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, Germany
| | - Caroline Wieczorek
- Authors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, GermanyAuthors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, GermanyAuthors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, Germany
| | - Jakob Schöttle
- Authors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, GermanyAuthors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, GermanyAuthors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, Germany
| | - Maike Siobal
- Authors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, GermanyAuthors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, GermanyAuthors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, Germany
| | - Yvonne Hinze
- Authors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, Germany
| | - Thomas Franz
- Authors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, Germany
| | - Alexandra Florin
- Authors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, Germany
| | - Joanna Adamczak
- Authors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, Germany
| | - Lukas C Heukamp
- Authors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, Germany
| | - Bernd Neumaier
- Authors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, Germany
| | - Roland T Ullrich
- Authors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, GermanyAuthors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, GermanyAuthors' Affiliations: Clinic I of Internal Medicine and Center for Integrated Oncology, University Hospital Cologne; Max Planck Institute for Neurological Research; Center for Molecular Medicine; Max Planck Institute for Biology of Aging; and Institute of Pathology, University Hospital Medical School, Cologne, Germany
| |
Collapse
|